-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 16th,
19 medicines, cancellation of bid qualifications
Recently, the Guizhou Provincial Pharmaceutical Centralized Procurement Platform issued the "Notice on Canceling the Qualification of the Third Batch of Partial Medicines in 2021"
.
The notice shows that a group of pharmaceutical companies have submitted applications for canceling the qualification of drug bidding/networking on the Guizhou Province Pharmaceutical Centralized Purchasing Platform, and promised that, starting from the date of cancellation, the company will not participate in the province’s centralized drug procurement activities for the same product within two years.
.
The list is as follows: Judging from the cancellation of the bid-winning qualifications of the above varieties in Guizhou and the promise that they will not participate in the collection of medicines in Guizhou within two years, there will still be a certain impact
.
According to data from the Guizhou Provincial Health Commission, as of 2019, there are 282 public hospitals and 1,370 health centers in Guizhou Province , which means that these drugs will lose the market for 1,370 hospitals in the next two years
.
The pressure of the medical representatives came.
From the perspective of the varieties that have been disqualified from winning the bid, some are still non-selected varieties purchased by the state , that is, varieties that have been evaluated but have not been purchased by the national volume procurement agreement, so they can only go to other non-selected varieties.
Divide the share of hospital purchases other than the selected varieties together
.
With the combination of recruitment and procurement and medical insurance, the "domino effect" of the country's mass procurement of unselected varieties has started
.
With the advancement of the country's centralized procurement, more and more unselected varieties will usher in a cruel price "fight"
.
For products that have not won the bid, they must face the original research drug and the product that has not passed the consistency evaluation, and compete for the remaining market of the national procurement.
The procurement method is that each medical institution purchases other provincial bid-winning and online varieties
.
The bitterness of this is hard to dismantle
.
The volume purchase did not win the bid, and the market share was greatly reduced, and the sales expenses could only be greatly reduced to maintain profitable enterprises
.
It is also necessary to fight for prices with competing products, fight for promotion capabilities, and fight fiercely in a limited market
.
As competition becomes increasingly day-to-day, more and more products will be eliminated or will choose to actively withdraw from market competition
.
In addition to products that have not been reviewed, there are also unreviewed products that have a huge impact
.
According to the policy requirements, “If there are more than 3 companies with the same product that have passed the consistency evaluation, the procurement of the product that has not passed the consistency evaluation will be suspended.
” Therefore, for those pharmaceutical representatives who are responsible for generic drugs that have not passed the consistency evaluation, they will face Greater pressure, because they can only passively exit the market
.
In addition, according to the State Food and Drug Administration requirements, chemical drugs newly registered varieties of generic drugs containing essential drugs, including the implementation of the classification approved for marketing before, since the first varieties through consistency evaluation, in principle, the same variety of other drug manufacturers should be in Complete the consistency evaluation within 3 years
.
As more and more varieties have passed the consistency evaluation, the three-year period after the first evaluation is a pressure for many pharmaceutical companies, and it is also a driving force for continuous progress
.
Otherwise, it is not only the hospital market that will be lost, but also the drug approval documents
.
With the intensive promulgation of policies and documents for the consistency evaluation of generic drugs, and the advancement of the country's mass procurement, many pharmaceutical companies have realized that the consistency evaluation of generic drugs is the general trend
.
Not only do it, but do it early
.
For medical representatives, the future selection of products should also pay more attention to their competitiveness in order to have better development
.
19 medicines, cancellation of bid qualifications
Recently, the Guizhou Provincial Pharmaceutical Centralized Procurement Platform issued the "Notice on Canceling the Qualification of the Third Batch of Partial Medicines in 2021"
.
The notice shows that a group of pharmaceutical companies have submitted applications for canceling the qualification of drug bidding/networking on the Guizhou Province Pharmaceutical Centralized Purchasing Platform, and promised that, starting from the date of cancellation, the company will not participate in the province’s centralized drug procurement activities for the same product within two years.
.
The list is as follows: Judging from the cancellation of the bid-winning qualifications of the above varieties in Guizhou and the promise that they will not participate in the collection of medicines in Guizhou within two years, there will still be a certain impact
.
According to data from the Guizhou Provincial Health Commission, as of 2019, there are 282 public hospitals and 1,370 health centers in Guizhou Province , which means that these drugs will lose the market for 1,370 hospitals in the next two years
.
The pressure of the medical representatives came.
From the perspective of the varieties that have been disqualified from winning the bid, some are still non-selected varieties purchased by the state , that is, varieties that have been evaluated but have not been purchased by the national volume procurement agreement, so they can only go to other non-selected varieties.
Divide the share of hospital purchases other than the selected varieties together
.
With the combination of recruitment and procurement and medical insurance, the "domino effect" of the country's mass procurement of unselected varieties has started
.
With the advancement of the country's centralized procurement, more and more unselected varieties will usher in a cruel price "fight"
.
For products that have not won the bid, they must face the original research drug and the product that has not passed the consistency evaluation, and compete for the remaining market of the national procurement.
The procurement method is that each medical institution purchases other provincial bid-winning and online varieties
.
The bitterness of this is hard to dismantle
.
The volume purchase did not win the bid, and the market share was greatly reduced, and the sales expenses could only be greatly reduced to maintain profitable enterprises
.
It is also necessary to fight for prices with competing products, fight for promotion capabilities, and fight fiercely in a limited market
.
As competition becomes increasingly day-to-day, more and more products will be eliminated or will choose to actively withdraw from market competition
.
In addition to products that have not been reviewed, there are also unreviewed products that have a huge impact
.
According to the policy requirements, “If there are more than 3 companies with the same product that have passed the consistency evaluation, the procurement of the product that has not passed the consistency evaluation will be suspended.
” Therefore, for those pharmaceutical representatives who are responsible for generic drugs that have not passed the consistency evaluation, they will face Greater pressure, because they can only passively exit the market
.
In addition, according to the State Food and Drug Administration requirements, chemical drugs newly registered varieties of generic drugs containing essential drugs, including the implementation of the classification approved for marketing before, since the first varieties through consistency evaluation, in principle, the same variety of other drug manufacturers should be in Complete the consistency evaluation within 3 years
.
As more and more varieties have passed the consistency evaluation, the three-year period after the first evaluation is a pressure for many pharmaceutical companies, and it is also a driving force for continuous progress
.
Otherwise, it is not only the hospital market that will be lost, but also the drug approval documents
.
With the intensive promulgation of policies and documents for the consistency evaluation of generic drugs, and the advancement of the country's mass procurement, many pharmaceutical companies have realized that the consistency evaluation of generic drugs is the general trend
.
Not only do it, but do it early
.
For medical representatives, the future selection of products should also pay more attention to their competitiveness in order to have better development
.
